UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

Aviles-Olmos, I; Dickson, J; Kefalopoulou, Z; Djamshidian, A; Kahan, J; Ell, P; Whitton, P; ... Foltynie, T; + view all (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. Journal of Parkinson’s Disease , 4 (3) 337 - 344. 10.3233/JPD-140364. Green open access

[img]
Preview
Text
jpd%2F2014%2F4-3%2Fjpd-4-3-jpd140364.pdf

Download (259kB) | Preview

Abstract

Background: Data from an open label randomised controlled trial have suggested possible advantages on both motor and non-motor measures in patients with Parkinson's disease following 12 months exposure to exenatide. Objective: Continued follow up of these same patients was performed to investigate whether these possible advantages persisted in the prolonged absence of this medication. Methods: All participants from an open label, randomised controlled trial of exenatide as a treatment for Parkinson’s disease, were invited for a further follow up assessment at the UCL Institute of Neurology. This visit included all 20 individuals who had previously completed twelve months exposure to exenatide 10ug bd and the 24 individuals who had acted as randomised controls. Motor severity of PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the MDS-UPDRS, together with several non-motor tests. This assessment was thus 24 months after their original baseline visit, i.e. 12 months after cessation of exenatide. Results: Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2–9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale. There was also a difference of 5.3 points; (95% CI, 9.3–1.4; p = 0.006) between the 2 groups on the Mattis Dementia Rating scale. Conclusions: While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson’s disease.

Type: Article
Title: Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.3233/JPD-140364
Publisher version: http://dx.doi.org/10.3233/JPD-140364
Language: English
Additional information: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Parkinson's disease, UPDRS, clinical trial, diabetes mellitus, disease modifying treatment, exenatide
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: http://discovery.ucl.ac.uk/id/eprint/1426265
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item